The United States Food & Drug Administration (US FDA) has completed the surveillance inspection of Casper Pharma Private Limited in Hyderabad (WOS of Suven Pharmaceuticals Limited).

The inspection took place from July 8, 2024, to July 12, 2024.

Following the inspection, we have been issued a Form 483 with two observations, which are procedural in nature. We are committed to addressing these observations within the stipulated timeline.